Biovance Capital Secures Series A Funding for Mondego Bio's Innovative Cancer Treatments Biovance Capital has led a significant Series A funding round for Mondego Bio, a startup focused on pioneering cancer therapies. Their work on PTPN2 inhibitors shows promise for improving immunotherapy outcomes.

Biovance Capital Secures Series A Funding for Mondego Bio's Innovative Cancer Treatments #Portugal #Lisbon #Biovance_Capital #Mondego_Bio #PTPN2_inhibitors